Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Efficacy Data
-
Can we present non-significant (N/S) efficacy data in an APS that is included in the Product Monograph (Part II: Clinical trials section)? Does it matter if it’s a primary, secondary or exploratory endpoint? If we can present N/S efficacy data, what parameters are required in order to present these in an APS?
-
